![]() Side effects in the former courses and latter courses were compared taking into account a stratification of intervals. To investigate whether the association between interval and treatment response could be modified by RAI treatment times, we performed a stratified analysis by RAI treatment times of the former course (second, third and fourth, and fifth and more). Therefore, the overall treatment response in the latter course was determined to be an effective response if SD or remission was obtained according to biochemical and structural response if either of biochemical response or structural response assessment indicated PD, the treatment response was determined to be a non-effective response. Meanwhile, the structural response in the latter course was categorized as structural CR, PR, SD, and PD, according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1-like criteria ( 20, 21). Eligible course pairs were then categorized into two groups according to the interval between courses: 1) −25.0% and ≤ 25.0% indicated stable disease (SD), and Δs-Tg% > 25.0% indicated progressive disease (PD). DTC patients with lung metastases have a relatively poorer prognosis than those without metastases, with a median survival of 60.0 IU/ml 4) course pairs with an interval >24 months because of poor compliance and 5) course pairs with missing treatment data. It was feasible to defer repeat evaluation and treatment with an interval of at least 12 months to obtain an effective response and reduce the risk of side effects.Īpproximately 10% of patients with differentiated thyroid cancer (DTC) have distant metastases at presentation or during follow-up, and their lungs are the most common organ of distant metastases, accounting for 70% of distant metastasis cases ( 1, 2). There was no significant difference in the side effects in the former and latter courses between the two groups (p > 0.05).Ĭonclusion: The interval of RAI treatment does not affect short-term response and side effects of DTC patients with RAI-avid lung metastases. Methods: A total of 282 course pairs from 91 patients were established and categorized into two groups by the interval of neighboring RAI treatment ( 0.05). We aim to investigate the association between the interval of RAI treatment and short-term response, and the side effects in patients with lung metastases from DTC and to identify predictors for non-effective response to the next RAI treatment. Objective: Repeat radioiodine (RAI) treatment has been widely implemented for RAI-avid lung metastases and is clinically effective for lung metastatic differentiated thyroid cancer (DTC). 2Department of Nuclear Medicine, Chengdu Fifth People’s Hospital, Chengdu, Sichuan, China.1Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.Hongxi Wang 1†, Lei Shi 2†, Rui Huang 1, Bin Liu 1 and Rong Tian 1*‡
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |